The US Food and Drug Administration and European Medicines Agency have recently approved a new drug class, injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapies (eg, once-daily liraglutide (7), once-weekly exenatide (8), and once-weekly dulaglutide) (9), for use in pediatric T2D for treatment alone or in combination with metformin and/or insulin (3, 6). This evidence concerns the gene INS and type 2 diabetes mellitus.